Beckman Coulter/Princeton BioMeditech agreement
In a move that underscores its growing commitment to the market for rapid diagnostic medical test products, Beckman Coulter has entered into a supply relationship with Princeton BioMeditech (PBM). Under the agreement, PBM will supply a wide range of rapid diagnostic tools used at the point of medical care to Beckman Coulter's Primary Care Diagnostics business unit (PCD).
Princeton BioMeditech is a leading innovator and manufacturer of simple and rapid diagnostic products used at the point of care. The company offers more than 70 tests covering fertility management, infectious diseases, cardiac markers, drugs of abuse, cancer markers, environmental and veterinary diagnostics that enable consumers and professionals to improve speed and quality of diagnosis for better patient care.
Australia–Vietnam collaborative research projects — applications open
Until 20 July, grant applications for projects in recycling and waste management, a sustainable...
AI and deep-tech research program receives $400K grant
A program designed to help scientists transform AI and deep-tech research into commercially...
Horizon Europe negotiations conclude
Once associated, Australian researchers and entities will be able to access Horizon Europe...
